Initiation of pitavastatin reduces major cardiovascular events in adults with HIV, suggesting improved ASCVD outcomes.
Initiation of pitavastatin in adults aged 40 to 75 living with HIV treated with highly active antiretroviral therapy (HAART) with low-to-moderate 10-year atherosclerotic cardiovascular disease (ASCVD) risk decreases the incidence of major cardiovascular events (MACE).
No takes yet. Share an insight, caveat, or question.
Garner et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: